UG1EY028091
Cooperative Agreement
Overview
Grant Description
Adalimumab vs. conventional immunosuppression for uveitis (ADVISE) trial.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Maryland
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 08/31/23 to 08/31/25 and the total obligations have increased 1087% from $758,746 to $9,004,458.
The Johns Hopkins University was awarded
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial
Cooperative Agreement UG1EY028091
worth $9,004,458
from National Eye Institute in September 2018 with work to be completed primarily in Maryland United States.
The grant
has a duration of 7 years and
was awarded through assistance program 93.867 Vision Research.
The Cooperative Agreement was awarded through grant opportunity NEI Clinical Vision Research: Coordinating Center Grant (UG1).
Status
(Complete)
Last Modified 8/5/24
Period of Performance
9/30/18
Start Date
8/31/25
End Date
Funding Split
$9.0M
Federal Obligation
$0.0
Non-Federal Obligation
$9.0M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for UG1EY028091
Transaction History
Modifications to UG1EY028091
Additional Detail
Award ID FAIN
UG1EY028091
SAI Number
UG1EY028091-2100433252
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NW00 NIH NATIONAL EYE INSTITUTE
Funding Office
75NW00 NIH NATIONAL EYE INSTITUTE
Awardee UEI
FTMTDMBR29C7
Awardee CAGE
5L406
Performance District
MD-90
Senators
Benjamin Cardin
Chris Van Hollen
Chris Van Hollen
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Eye Institute, National Institutes of Health, Health and Human Services (075-0887) | Health research and training | Grants, subsidies, and contributions (41.0) | $9,037,917 | 100% |
Modified: 8/5/24